Gefitinib (Gefitinib) Patent Expiration, LOE Window & CMS Spending

Gefitinib (Gefitinib) by Ingenus Pharmac: Multi-Source Generic Molecule, 3 AB generics, $2.6M 2024 CMS Part D & Medicaid spend, and $7,103 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIngenus Pharmac
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$2.6M
2024 Medicare Part D Spend$2.5M
2024 Medicaid Spend$161K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($7,103 intro WAC)